The Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge. ArcticZymes Q2 report Sales of NOK 44.3 million (16.9) +262% EBITDA of NOK 27.2 million (-0.5) Cash-flow for the Q2 was NOK 20.4 million (-6.8) Cash at...
AMBU has broken this slightly bearish wedge in a stron bullish uptrend during corona. One could wait to see that this week closes over the indicated wedge.
Could maybe fall back to 370 DKK for a good buying spot for longs
Solid allergy company in the healthcare sector. Roof of trend channel is app. at 2330 DKK and bottom of the trend channel is at 1740 DKK.
AMBU has taken a break since april 2020 after a very nice rally in 2020 due to hospitals mass buy of AMBU's respiratory equipment. The trend is still up and if it can break 230 DKK the next days/weeks, it would signal further increase in the stock price. Maybe all the way to the top of the trend channel at 330 DKK
Largest owner in Photocure OSL:PHO apparently being forced to dump the whole position in the stock in the course of a few days, giving the stock extra momentum to the downside. Updated list of shareholders show influx of US actors. twitter.com
Hi, Navamedic ASA, a MedTech and pharmaceutical company, in-licenses, buys and markets pharmaceuticals and other health care products in the Northern European region. Considering technical viewpoints then Navamedic has started to approach a pretty strong support area, a lot of criteria make up a strong crossing area. To be honest, I don't know much about...
Coloplast is in a solid uptrend that goes years back. However, this resistance needs to be crossed in order for it to go higher. One could then wait for a small retracement to the black line that then needs to hold as support for it to bounce further up to 900 DKK
Friday, October 11, 2019 ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the...
Conformis Inc. (Nasdaq: CFMS) is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture & sell patient specific joint replacement implants. The implants are designed to fit each patient's unique anatomy. CFMS stated in their previous ER (July 31, 2019), the company was updating their 2019 outlook...
About CFMS Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy. Technicals Bullish Gartley pattern (786 retracement) Fibonacci...
Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here . Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float. Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame. Follow me on twitter and...
As mentioned in an earlier Idea ( ), the Q4 report represented a substantial risk for a downwards reaction after a recent surge in the share price. At the new price level around NOK 41 the stock is much more attractively priced, and this could be the time to move in for new investors.